Leslie Trigg Sells 14,611 Shares of Outset Medical, Inc. (NASDAQ:OM) Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 14,611 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $0.90, for a total transaction of $13,149.90. Following the sale, the chief executive officer now directly owns 880,969 shares in the company, valued at $792,872.10. This represents a 1.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Leslie Trigg also recently made the following trade(s):

• On Tuesday, January 21st, Leslie Trigg sold 65,236 shares of Outset Medical stock. The stock was sold at an average price of $0.80, for a total value of $52,188.80.
• On Monday, January 13th, Leslie Trigg sold 33,227 shares of Outset Medical stock. The shares were sold at an average price of $0.81, for a total value of $26,913.87.
• On Tuesday, January 7th, Leslie Trigg sold 10,227 shares of Outset Medical stock. The stock was sold at an average price of $1.29, for a total value of $13,192.83.

Outset Medical Price Performance

Shares of Outset Medical stock traded up $0.03 during midday trading on Wednesday, reaching $0.94. The company had a trading volume of 1,533,329 shares, compared to its average volume of 1,386,158. The company has a current ratio of 6.49, a quick ratio of 5.04 and a debt-to-equity ratio of 4.12. The stock has a fifty day simple moving average of $0.96 and a 200 day simple moving average of $0.85. Outset Medical, Inc. has a 1-year low of $0.44 and a 1-year high of $5.22. The company has a market capitalization of $50.48 million, a price-to-earnings ratio of -0.34 and a beta of 2.01.

Outset Medical (NASDAQ:OM) last released its earnings results on Wednesday, February 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). Outset Medical had a negative net margin of 122.84% and a negative return on equity of 164.92%. As a group, equities research analysts forecast that Outset Medical, Inc. will post -2.52 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of OM. National Bank of Canada FI lifted its holdings in Outset Medical by 79.2% in the third quarter. National Bank of Canada FI now owns 52,407 shares of the company’s stock valued at $35,000 after buying an additional 23,164 shares during the period. Huntington National Bank raised its position in shares of Outset Medical by 46.2% during the 3rd quarter. Huntington National Bank now owns 63,306 shares of the company’s stock valued at $43,000 after acquiring an additional 20,000 shares during the last quarter. Two Sigma Securities LLC lifted its stake in shares of Outset Medical by 190.0% in the 4th quarter. Two Sigma Securities LLC now owns 42,477 shares of the company’s stock valued at $47,000 after purchasing an additional 27,830 shares during the period. XTX Topco Ltd bought a new position in shares of Outset Medical in the 4th quarter worth $50,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Outset Medical during the fourth quarter worth $174,000.

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $3.00 price target on shares of Outset Medical in a report on Tuesday, January 7th.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.